

DXS International plc

AGM

18th December 2025



WELCOME

- A year ago, we expressed our frustration with the lack of revenue growth.
- We are focused in delivering on our plan and remain 100% of the conviction that, at DXS, we have solutions that are aligned with the NHS plan to resolve their problems.
- We are positive that the NHS is moving in the right direction with regards to their commitment to digital transformation as one solution.

RESULTS FOR YEAR END APRIL 2025

DXS011124

5% Revenue Increase



Operating Loss Reduced




EBITDA Improved




SMART REFERRALS HIGHLIGHTS FOR THE YEAR

1.8 Million Referrals



15% of all England Referrals

Referral Outcomes



New Technology



New Revenue

Leveraging off existing user base

Following the recent ICB restructuring from 160 CCGs to 42 ICBs resulted in 5 of our ICB customers having approximately 270 GP practices not using our DXS Smart Referral solution while the majority of their practices did.


Opportunity

These five ICBs have indicated that they are keen to standardise on DXS as a single referral solution


Potential new annual revenue of 30% increase p.a.

WHAT THIS COULD MEAN

27% Price Increase could increase existing revenue significantly due to NHS framework renewal



Potential expansion in Existing Customers could equate to a 30% increase in annual NHS revenue p.a.



Potential New Customers



SECONDARY CARE HIGHLIGHTS FOR THE YEAR

DXS Team currently create 1,000's of bespoke referral forms for speciality units



These forms are put into GP systems enabling GPs to send the right form with the right info to each speciality unit



Currently 1.8 million referrals sent p.a. and growing



153 Adult Speciality Types

2,000 plus speciality units across 200 hospitals

Examples of speciality units

Adult specialist respiratory services

Adult specialist rheumatology services

Adult secure mental health services

Adult specialist cardiac services

Adult specialist endocrinology services

Adult specialist ophthalmology services

Adult specialist orthopaedic services

Adult specialist pulmonary hypertension services

Adult specialist renal services

Currently 1.8 million referrals and growing

Average admin time per referral of 20 min.


DXS Solution can save 10 minutes per referral, an annual potential saving of £4.6 million.

DXS plan to charge £0.60 per referral.

We are targeting 25% of existing referrals

Growing our existing footprint could easily double this revenue.

EXPERTCARE HIGHLIGHTS FOR THE YEAR



MEDICINE INFORMATION

Monitored by the Association of the
British Pharmaceutical Industry



DXS continue to provide a
medicine information channel to
GP practices throughout the UK
for most major pharma
companies.

New exciting development plans to open up new promotion opportunities
for the pharma industry.

WHAT OUR USERS SAY



"Generally speaking the ease with which I can search for word, find the form, fill in the relevant bits along with the auto-population, and then save/email it off immediately is really satisfying. If

I think about where we were with our referral processes and access to pathways across primary care before the CCG commissioned this platform, and you and your colleagues put in all the hard work, it was a million miles away from what we have now and take for granted. I bet you anything that if it all packed up tomorrow we'd hear nothing but moaning about wanting it back and how much better life was when we had it!"

Dr Richard Pile

GP Partner & Cardiology GPSI
Herts Valleys CCG board member



Sarah Dekmak

Head of Operations
Lead Clinical Pharmacist (IP)

"ExpertCare is fast,
accurate, and reliable.
It is a game changer."

THE FUTURE ROADMAP

Partnering with a development house to build a suite of SMART Pathways. This initiative aligns with the NHS strategy of standardising pathways to ensure continuity and reduce variation in care.

DXS awarded a bronze medal in a US competition to help create innovation awareness. From DXS's perspective, this was a long shot – designed purely as an exercise to test US market appetite. Despite being UK-based in an all-American field of competitors, we managed to progress to the semi-finals and were ultimately awarded a bronze certificate. Coming 3rd out of a field of 12 finalists.



OUR COMMITMENT TO GREEN SUSTAINABILITY



943.6 tonnes CO2



8,657 Trees planted



**57,742 m² Land
reforested**



Congratulations!

Your company has been awarded a Bronze Medal in recognition of your sustainability achievement.

[Learn about the EcoVadis Medals & Badges Program](#)

Overall score

Percentile

76th ⓘ

↗ **64**/100



Environment

↗ **69**/100



**Labor & Human
Rights**

↗ **63**/100




Ethics

↘ **63**/100



**Sustainable
Procurement**

↗ **62**/100



SUMMARY



DXS Solutions

Ten-Year Digital Transformation Plan

NHS has identified:

- Digital innovation
- And preventive care as key priorities
- With targeted funding directed toward high-impact, technology-driven solutions.



CVD healthcare
costs estimate



CVD economic
cost estimate

FOCUSED ON ACHIEVING SHAREHOLDER VALUE

- At DXS, however frustrating the delays have been for shareholders, management and employees remain focused with conviction to turn delays into opportunity which we have used to build and innovate on.
- We are sensing a shift in NHS urgency at ICB level to resolve problems.
- We finally have the sense that we expect revenue to begin to grow around April 2026.

Income Statement
Year Ended April 2025

	2025 Continuing Operations £	2024 Continuing Operations £
Turn over	3,469,917	3,308,359
Cost of sales	(479,382)	(428,212)
Gross Profit	2,990,535	2,880,147
Grant income	132,993	136,570
Administration costs	(3,251,011)	(2,494,510)
Depreciation, amortisation and impairment		
Depreciation and amortisation	(1,038)	(1,020,916)
Impairment	-	(4,378,114)
	(1,038)	(5,399,030)
Operating Loss	(128,521)	(4,876,823)
Sundry income	1,898	15
	(126,623)	(4,876,808)
Interest payable and similar expenses	(48,525)	(74,842)
Loss on ordinary activities before taxation	(175,148)	(4,951,650)
Tax on loss on ordinary activities	80,398	212,964
Loss for the year	(94,750)	(4,738,686)
Earnings per share-		
- basic	(0.1p)	(7.4p)
- fully diluted	(0.1p)	(7.4p)

Statement of Financial Position As at 30 April 2025

	Group	Group	Company	Company
	2025	2024	2025	2024
	£	£	£	£
Fixed assets				
Intangible assets	1,455,000	1,455,000	-	-
Tangible assets	-	1,038	-	-
Investments	<u>-</u>	<u>-</u>	<u>535,768</u>	<u>507,954</u>
	<u>1,455,000</u>	<u>1,456,038</u>	<u>535,768</u>	<u>507,954</u>
Current assets				
Debtors: amounts falling due within one year	486,556	1,115,272	44,507	196,024
Cash at bank and in hand	<u>428,957</u>	<u>90,012</u>	<u>16,810</u>	<u>4,094</u>
	915,513	1,205,284	61,317	200,118
Creditors: amounts falling due within one year	<u>(908,986)</u>	<u>(811,205)</u>	<u>(143,674)</u>	<u>(161,124)</u>
Net current assets	<u>6,527</u>	<u>394,079</u>	<u>(82,357)</u>	<u>38,994</u>
Total assets less current liabilities	1,461,527	1,850,117	453,411	546,948
Creditors				
Amounts falling due after more than one year	(285,353)	(345,455)	(95,939)	(99,562)
Deferred income	<u>(814,542)</u>	<u>(1,057,276)</u>	<u>-</u>	<u>-</u>
	<u>361,632</u>	<u>447,386</u>	<u>357,472</u>	<u>447,386</u>
Capital and reserves				
Called up share capital	211,273	211,273	211,273	211,273
Share premium	3,213,395	3,213,395	3,213,395	3,213,395
Share option reserve	15,159	11,589	15,159	11,589
Retained earnings	<u>(3,078,195)</u>	<u>(2,988,871)</u>	<u>(3,082,355)</u>	<u>(2,988,871)</u>
Shareholders' funds	<u>361,632</u>	<u>447,386</u>	<u>357,472</u>	<u>447,386</u>

THANK YOU